Weekly FDA Drug Pipeline Calendar (April 10 - April 14)

The FDA has granted Emergency Use Authorization (EUA) for Gohibic (vilobelimab) to $InflaRx (IFRX.US)$ for the treatment of COVID-19 in hospitalized adults, provided it is initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Shares closed the week up 184% at $5.50.

An analyst from Oppenheimer has reaffirmed their Outperform rating on $Eloxx Pharmaceuticals (ELOX.US)$ and kept the price target at $50. Shares closed the week up 151% at $5.64.

A non-binding all-cash proposal has been submitted by Thomvest Asset Management Ltd. to acquire all outstanding common shares of $Liminal BioSciences (LMNL.US)$ for $7.50 per share. However, the proposal excludes the 64% stake held by Structured Alpha LP, in which Thomvest is the sole general partner. Shares closed the week up 79% at $6.82.

$Clearmind Medicine (CMND.US)$ has announced a public offering of 4,505,718 common shares and pre-funded warrants for $3.5 million, at a rate of $0.78 per share. Shares closed the week down 70% at $0.38.

Thursday, April 13, 2023
PDUFA $Teva Pharmaceutical Industries (TEVA.US)$ ALVO AVT02 - (Humira biosimilar)
Producer Price Index (PPI) - March 8:30 am ET
Initial Jobless Claims - April 8 8:30 am ET